Validation of neurodegeneration screen hits in zebrafish: functional analysis of drug effects on neural activity

The OCE-CQDM Life Sciences R&D Challenge program is a groundbreaking collaboration between researchers at St.Michael’s Hospital (SMH) and Treventis Corporation (both in Toronto), as well as the University of Montreal (Dr. Drapeau, an expert in zebrafish models of disease). The zebrafish is a robust model for translational research because of our understanding of zebrafish biology and its overlap with that of humans.

Assessment of a novel chemical entity (TRV 1387) in the treatment of tau-related neuropathology and behavioral impairment in a transgenic mouse model of Alzheimer’s disease

The onset of symptoms in Alzheimer’s Disease, Picks disease, progressive supranuclear palsy and cortical basal degeneration are connected to the formation of insoluble deposits of the tau protein in the brain, also known as neurofibrillary tangles (NFT). The Treventis Corporation has developed new chemicals that are designed to prevent the formation of NFT, which may be useful for treating Alzheimer’s disease.

Assessment of a novel chemical entity (TRV 1387) in the treatment of tau-related neuropathology and behavioral impairment in a transgenic mouse model of Alzheimer’s disease

The onset of symptoms in Alzheimer’s Disease, Picks disease, progressive supranuclear palsy and cortical basal degeneration are connected to the formation of insoluble deposits of the tau protein in the brain, also known as neurofibrillary tangles (NFT). The Treventis Corporation has developed new chemicals that are designed to prevent the formation of NFT, which may be useful for treating Alzheimer’s disease.